Canadian Province Expands Biosimilar Switching, But Patient Group Voices Concerns

 
• By Aidan Fry

British Columbia’s move to switch gastrointestinal patients to biosimilar infliximabs by March 2020 has pleased local industry but upset an originator-backed patients’ group.

Cockpit
Patients with Crohn's disease and ulcerative colitis are to be switched to biosimilars in Canada's British Columbia province • Source: Shutterstock

More from Biosimilars

More from Products